Literature DB >> 25838279

Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy.

Martin F M de Rooij1, Annemieke Kuil1, Arnon P Kater2, Marie José Kersten2, Steven T Pals3, Marcel Spaargaren3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25838279      PMCID： PMC4416940          DOI： 10.1182/blood-2014-12-619163

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  9 in total

1.  The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia.

Authors:  Martin F M de Rooij; Annemieke Kuil; Christian R Geest; Eric Eldering; Betty Y Chang; Joseph J Buggy; Steven T Pals; Marcel Spaargaren
Journal:  Blood       Date:  2012-01-25       Impact factor: 22.113

2.  Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

Authors:  Jennifer A Woyach; Richard R Furman; Ta-Ming Liu; Hatice Gulcin Ozer; Marc Zapatka; Amy S Ruppert; Ling Xue; Daniel Hsieh-Hsin Li; Susanne M Steggerda; Matthias Versele; Sandeep S Dave; Jenny Zhang; Ayse Selen Yilmaz; Samantha M Jaglowski; Kristie A Blum; Arletta Lozanski; Gerard Lozanski; Danelle F James; Jacqueline C Barrientos; Peter Lichter; Stephan Stilgenbauer; Joseph J Buggy; Betty Y Chang; Amy J Johnson; John C Byrd
Journal:  N Engl J Med       Date:  2014-05-28       Impact factor: 91.245

3.  A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL).

Authors:  Brad S Kahl; Stephen E Spurgeon; Richard R Furman; Ian W Flinn; Steven E Coutre; Jennifer R Brown; Don M Benson; John C Byrd; Sissy Peterman; Yoonjin Cho; Albert Yu; Wayne R Godfrey; Nina D Wagner-Johnston
Journal:  Blood       Date:  2014-03-10       Impact factor: 22.113

4.  Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

Authors:  Jennifer R Brown; John C Byrd; Steven E Coutre; Don M Benson; Ian W Flinn; Nina D Wagner-Johnston; Stephen E Spurgeon; Brad S Kahl; Celeste Bello; Heather K Webb; Dave M Johnson; Sissy Peterman; Daniel Li; Thomas M Jahn; Brian J Lannutti; Roger G Ulrich; Albert S Yu; Langdon L Miller; Richard R Furman
Journal:  Blood       Date:  2014-03-10       Impact factor: 22.113

5.  P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.

Authors:  Sunil Iyengar; Andrew Clear; Csaba Bödör; Lenushka Maharaj; Abigail Lee; Maria Calaminici; Janet Matthews; Sameena Iqbal; Rebecca Auer; John Gribben; Simon Joel
Journal:  Blood       Date:  2013-01-22       Impact factor: 22.113

6.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245

7.  Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients.

Authors:  Betty Y Chang; Michelle Francesco; Martin F M De Rooij; Padmaja Magadala; Susanne M Steggerda; Min Mei Huang; Annemieke Kuil; Sarah E M Herman; Stella Chang; Steven T Pals; Wyndham Wilson; Adrian Wiestner; Marcel Spaargaren; Joseph J Buggy; Laurence Elias
Journal:  Blood       Date:  2013-08-12       Impact factor: 22.113

8.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

9.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
  9 in total
  34 in total

1.  The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Authors:  R Thijssen; J Ter Burg; G G W van Bochove; M F M de Rooij; A Kuil; M H Jansen; T W Kuijpers; J W Baars; A Virone-Oddos; M Spaargaren; C Egile; M H J van Oers; E Eldering; M J Kersten; A P Kater
Journal:  Leukemia       Date:  2015-09-04       Impact factor: 11.528

2.  Ibrutinib and idelalisib target B cell receptor- but not CXCL12/CXCR4-controlled integrin-mediated adhesion in Waldenström macroglobulinemia.

Authors:  Martin F M de Rooij; Annemieke Kuil; Willem Kraan; Marie José Kersten; Steven P Treon; Steven T Pals; Marcel Spaargaren
Journal:  Haematologica       Date:  2015-12-03       Impact factor: 9.941

3.  Discovery of Pyrazolopyrimidine Derivatives as Novel Dual Inhibitors of BTK and PI3Kδ.

Authors:  Brahmam Pujala; Anil K Agarwal; Sandip Middya; Monali Banerjee; Arjun Surya; Anjan K Nayak; Ashu Gupta; Sweta Khare; Rambabu Guguloth; Nitin A Randive; Bharat U Shinde; Anamika Thakur; Dhananjay I Patel; Mohd Raja; Michael J Green; Jennifer Alfaro; Patricio Avila; Felipe Pérez de Arce; Ramona G Almirez; Stacy Kanno; Sebastián Bernales; David T Hung; Sarvajit Chakravarty; Emma McCullagh; Kevin P Quinn; Roopa Rai; Son M Pham
Journal:  ACS Med Chem Lett       Date:  2016-10-28       Impact factor: 4.345

4.  CLL: ibrutinib and transplantation ride together.

Authors:  E Montserrat; J Delgado
Journal:  Bone Marrow Transplant       Date:  2016-05-09       Impact factor: 5.483

Review 5.  PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.

Authors:  Benjamin L Lampson; Jennifer R Brown
Journal:  Expert Opin Investig Drugs       Date:  2017-10-06       Impact factor: 6.206

6.  Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.

Authors:  Matthew S Davids; Haesook T Kim; Alyssa Nicotra; Alexandra Savell; Karen Francoeur; Jeffrey M Hellman; Josie Bazemore; Hari P Miskin; Peter Sportelli; Laura Stampleman; Rodrigo Maegawa; Jens Rueter; Adam M Boruchov; Jon E Arnason; Caron A Jacobson; Eric D Jacobsen; David C Fisher; Jennifer R Brown
Journal:  Lancet Haematol       Date:  2018-12-14       Impact factor: 18.959

7.  Inhibition of B-cell receptor signaling disrupts cell adhesion in mantle cell lymphoma via RAC2.

Authors:  Wenjun Wu; Weige Wang; Carrie A Franzen; Hui Guo; Jimmy Lee; Yan Li; Madina Sukhanova; Dong Sheng; Girish Venkataraman; Mei Ming; Pin Lu; Anhui Gao; Chunmei Xia; Jia Li; Liang Leo Zhang; Vivian Changying Jiang; Michael L Wang; Jorge Andrade; Xiaoyan Zhou; Y Lynn Wang
Journal:  Blood Adv       Date:  2021-01-12

8.  Ibrutinib inhibits free fatty acid metabolism in chronic lymphocytic leukemia.

Authors:  Uri Rozovski; David M Harris; Ping Li; Zhiming Liu; Preetesh Jain; Alessandra Ferrajoli; Jan Burger; Phillip Thompson; Nitin Jain; William Wierda; Michael J Keating; Zeev Estrov
Journal:  Leuk Lymphoma       Date:  2018-02-21

9.  Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia.

Authors:  Elisa Ten Hacken; Mariela Sivina; Ekaterina Kim; Susan O'Brien; William G Wierda; Alessandra Ferrajoli; Zeev Estrov; Michael J Keating; Thomas Oellerich; Cristina Scielzo; Paolo Ghia; Federico Caligaris-Cappio; Jan A Burger
Journal:  J Immunol       Date:  2016-08-17       Impact factor: 5.422

10.  Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model.

Authors:  Yaya Chu; Sanghoon Lee; Tishi Shah; Changhong Yin; Matthew Barth; Rodney R Miles; Janet Ayello; Erin Morris; Lauren Harrison; Carmella Van de Ven; Paul Galardy; Stanton C Goldman; Megan S Lim; Michelle Hermiston; Linda M McAllister-Lucas; Lisa Giulino-Roth; Sherrie L Perkins; Mitchell S Cairo
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.